Supplementary Materials

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

Kristen E. Pauken, Morgan A. Sammons, Pamela M. Odorizzi, Sasikanth Manne, Jernej Godec, Omar Khan, Adam M. Drake, Zeyu Chen, Debattama Sen, Makoto Kurachi, R. Anthony Barnitz, Caroline Bartman, Bertram Bengsch, Alexander C. Huang, Jason M. Schenkel, Golnaz Vahedi, W. Nicholas Haining, Shelley L. Berger, E. John Wherry

Materials/Methods, Supplementary Text, Tables, Figures, and/or References

Download Supplement
  • Materials and Methods
  • Figs. S1 to S18
  • Captions for tables S1 to S12
  • References
Table S1
List of genes significantly differentially expressed following anti-PDL1 treatment.
Table S2
GSEA reports showing GO and KEGG pathways identified following anti-PDL1 treatment.
Table S3
Gene list and GSEA report for effector genes.
Table S4
List of genes identified using Leading Edge Metagene analysis and overlaps between cell types.
Table S5
Differentially expressed genes one day or 18-29 weeks after cessation of anti- PD-L1 treatment in the RNA-seq data set.
Table S6
GO term enrichments in the RNA-seq data set.
Table S7
List of ATAC-seq peaks annotated with nearest genes corresponding to distinct co-clusters.
Table S8
GO terms associated with ATAC-seq peaks gained exclusive to each cell type.
Table S9
Full list of transcription factor binding motifs present in open chromatin regions gained or lost in TEX following anti-PD-L1 treatment.
Table S10
Full list of transcription factors predicted to have uniquely enriched binding in OCRs in TN, TEFF, TMEM, TEX, or anti-PD-L1-treated TEX.
Table S11
Association of differentially expressed genes with transcription factors predicted to have altered activity in ATAC-seq data set.
Table S12
Transcription factors predicted to regulate differentially expressed genes following anti-PD-L1.